However, in a phase III SKYSCRAPER-02 trial of anti-PD-L1 Ab atezolizumab plus first-line chemotherapy with or without anti-TIGIT Ab tiragolumab in SCLC, tiragolumab did not provide an additional survival benefit [290]. Here, CD274 is linked to small cell lung carcinoma.